Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 97

1.

Authors' Reply to Lechat et al.: "Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?"

Concordet D, Gandia P, Montastruc JL, Bousquet-Mélou A, Lees P, Ferran AA, Toutain PL.

Clin Pharmacokinet. 2019 Aug 27. doi: 10.1007/s40262-019-00815-8. [Epub ahead of print] No abstract available.

PMID:
31452151
2.

Why Were More Than 200 Subjects Required to Demonstrate the Bioequivalence of a New Formulation of Levothyroxine with an Old One?

Concordet D, Gandia P, Montastruc JL, Bousquet-Mélou A, Lees P, Ferran AA, Toutain PL.

Clin Pharmacokinet. 2019 Aug 21. doi: 10.1007/s40262-019-00812-x. [Epub ahead of print]

PMID:
31432471
3.

Allelopathic effects of volatile organic compounds released from Pinus halepensis needles and roots.

Santonja M, Bousquet-Mélou A, Greff S, Ormeño E, Fernandez C.

Ecol Evol. 2019 Jul 2;9(14):8201-8213. doi: 10.1002/ece3.5390. eCollection 2019 Jul.

4.

Variability of the Ability of Complex Microbial Communities to Exclude Microbes Carrying Antibiotic Resistance Genes in Rabbits.

Achard CS, Dupouy V, Siviglia S, Arpaillange N, Cauquil L, Bousquet-Mélou A, Zemb O.

Front Microbiol. 2019 Jul 2;10:1503. doi: 10.3389/fmicb.2019.01503. eCollection 2019.

5.

Author's Reply to Trechot: "Comment on Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?"

Concordet D, Gandia P, Montastruc JL, Bousquet-Mélou A, Lees P, Ferran AA, Toutain PL.

Clin Pharmacokinet. 2019 Jul;58(7):979-980. doi: 10.1007/s40262-019-00787-9. No abstract available.

PMID:
31187472
6.

Authors' Reply to Castello-Bridoux et al.: "Comment on Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?"

Concordet D, Gandia P, Montastruc JL, Bousquet-Mélou A, Lees P, Ferran AA, Toutain PL.

Clin Pharmacokinet. 2019 Jul;58(7):973-975. doi: 10.1007/s40262-019-00786-w. No abstract available.

7.

Authors' Reply to Nicolas: "Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?"

Concordet D, Gandia P, Montastruc JL, Bousquet-Mélou A, Lees P, Ferran AA, Toutain PL.

Clin Pharmacokinet. 2019 Jul;58(7):961-963. doi: 10.1007/s40262-019-00781-1. No abstract available.

8.

Authors' Reply to Coste et al.: "Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?"

Concordet D, Gandia P, Montastruc JL, Bousquet-Mélou A, Lees P, Ferran AA, Toutain PL.

Clin Pharmacokinet. 2019 Jul;58(7):967-968. doi: 10.1007/s40262-019-00780-2. No abstract available.

9.

Comparison of hydroalcoholic rubbing and conventional chlorhexidine scrubbing for aseptic skin preparation in dogs.

Asimus E, Palierne S, Blondel M, Pollet V, Ferran A, Bousquet-Melou A, Rousselot JF, Autefage A.

Vet Surg. 2019 Apr 29. doi: 10.1111/vsu.13222. [Epub ahead of print]

PMID:
31034647
10.

Levothyrox® New and Old Formulations: Are they Switchable for Millions of Patients?

Concordet D, Gandia P, Montastruc JL, Bousquet-Mélou A, Lees P, Ferran A, Toutain PL.

Clin Pharmacokinet. 2019 Jul;58(7):827-833. doi: 10.1007/s40262-019-00747-3.

11.

Comparison of in vitro static and dynamic assays to evaluate the efficacy of an antimicrobial drug combination against Staphylococcus aureus.

Broussou DC, Toutain PL, Woehrlé F, El Garch F, Bousquet-Melou A, Ferran AA.

PLoS One. 2019 Jan 23;14(1):e0211214. doi: 10.1371/journal.pone.0211214. eCollection 2019.

12.

Population Pharmacokinetic Study of Cefazolin Used Prophylactically in Canine Surgery for Susceptibility Testing Breakpoint Determination.

Cagnardi P, Di Cesare F, Toutain PL, Bousquet-Mélou A, Ravasio G, Villa R.

Front Pharmacol. 2018 Oct 9;9:1137. doi: 10.3389/fphar.2018.01137. eCollection 2018.

13.

A pressurized liquid extraction approach followed by standard addition method and UPLC-MS/MS for a fast multiclass determination of antibiotics in a complex matrix.

Ezzariai A, Riboul D, Lacroix MZ, Barret M, El Fels L, Merlina G, Bousquet-Melou A, Patureau D, Pinelli E, Hafidi M.

Chemosphere. 2018 Nov;211:893-902. doi: 10.1016/j.chemosphere.2018.08.021. Epub 2018 Aug 7.

PMID:
30119021
14.

Resistance of native oak to recurrent drought conditions simulating predicted climatic changes in the Mediterranean region.

Saunier A, Ormeño E, Havaux M, Wortham H, Ksas B, Temime-Roussel B, Blande JD, Lecareux C, Mévy JP, Bousquet-Mélou A, Gauquelin T, Fernandez C.

Plant Cell Environ. 2018 Oct;41(10):2299-2312. doi: 10.1111/pce.13331. Epub 2018 Jul 19.

PMID:
29749622
15.

Differential Activity of the Combination of Vancomycin and Amikacin on Planktonic vs. Biofilm-Growing Staphylococcus aureus Bacteria in a Hollow Fiber Infection Model.

Broussou DC, Lacroix MZ, Toutain PL, Woehrlé F, El Garch F, Bousquet-Melou A, Ferran AA.

Front Microbiol. 2018 Mar 27;9:572. doi: 10.3389/fmicb.2018.00572. eCollection 2018.

16.

En Route towards European Clinical Breakpoints for Veterinary Antimicrobial Susceptibility Testing: A Position Paper Explaining the VetCAST Approach.

Toutain PL, Bousquet-Mélou A, Damborg P, Ferran AA, Mevius D, Pelligand L, Veldman KT, Lees P.

Front Microbiol. 2017 Dec 15;8:2344. doi: 10.3389/fmicb.2017.02344. eCollection 2017. Review.

17.

Mixing of Shiga toxin-producing and enteropathogenic Escherichia coli in a wastewater treatment plant receiving city and slaughterhouse wastewater.

Bibbal D, Um MM, Diallo AA, Kérourédan M, Dupouy V, Toutain PL, Bousquet-Mélou A, Oswald E, Brugère H.

Int J Hyg Environ Health. 2018 Mar;221(2):355-363. doi: 10.1016/j.ijheh.2017.12.009. Epub 2017 Dec 29.

PMID:
29307571
18.

Prediction of human prenatal exposure to bisphenol A and bisphenol A glucuronide from an ovine semi-physiological toxicokinetic model.

Gauderat G, Picard-Hagen N, Toutain PL, Servien R, Viguié C, Puel S, Lacroix MZ, Corbel T, Bousquet-Melou A, Gayrard V.

Sci Rep. 2017 Nov 10;7(1):15330. doi: 10.1038/s41598-017-15646-5.

19.

Implementing Precision Antimicrobial Therapy for the Treatment of Bovine Respiratory Disease: Current Limitations and Perspectives.

Lhermie G, Toutain PL, El Garch F, Bousquet-Mélou A, Assié S.

Front Vet Sci. 2017 Aug 29;4:143. doi: 10.3389/fvets.2017.00143. eCollection 2017.

20.

Capacity limits of asialoglycoprotein receptor-mediated liver targeting.

Bon C, Hofer T, Bousquet-Mélou A, Davies MR, Krippendorff BF.

MAbs. 2017 Nov/Dec;9(8):1360-1369. doi: 10.1080/19420862.2017.1373924. Epub 2017 Sep 6.

21.

Infection-stage adjusted dose of beta-lactams for parsimonious and efficient antibiotic treatments: A Pasteurella multocida experimental pneumonia in mice.

Vasseur MV, Lacroix MZ, Toutain PL, Bousquet-Melou A, Ferran AA.

PLoS One. 2017 Aug 4;12(8):e0182863. doi: 10.1371/journal.pone.0182863. eCollection 2017.

22.

Impact of Low and High Doses of Marbofloxacin on the Selection of Resistant Enterobacteriaceae in the Commensal Gut Flora of Young Cattle: Discussion of Data from 2 Study Populations.

Lhermie G, Dupouy V, El Garch F, Ravinet N, Toutain PL, Bousquet-Mélou A, Seegers H, Assié S.

Foodborne Pathog Dis. 2017 Mar;14(3):152-159. doi: 10.1089/fpd.2016.2176. Epub 2017 Jan 10.

PMID:
28072925
23.

In vitro Degradation of Antimicrobials during Use of Broth Microdilution Method Can Increase the Measured Minimal Inhibitory and Minimal Bactericidal Concentrations.

Lallemand EA, Lacroix MZ, Toutain PL, Boullier S, Ferran AA, Bousquet-Melou A.

Front Microbiol. 2016 Dec 21;7:2051. doi: 10.3389/fmicb.2016.02051. eCollection 2016.

24.

Veterinary Medicine Needs New Green Antimicrobial Drugs.

Toutain PL, Ferran AA, Bousquet-Melou A, Pelligand L, Lees P.

Front Microbiol. 2016 Aug 3;7:1196. doi: 10.3389/fmicb.2016.01196. eCollection 2016. Review.

25.

Comparison of the In vitro Activity of Five Antimicrobial Drugs against Staphylococcus pseudintermedius and Staphylococcus aureus Biofilms.

Ferran AA, Liu J, Toutain PL, Bousquet-Mélou A.

Front Microbiol. 2016 Aug 2;7:1187. doi: 10.3389/fmicb.2016.01187. eCollection 2016.

26.

Dominant plasmids carrying extended-spectrum β-lactamases blaCTX-M genes in genetically diverse Escherichia coli from slaughterhouse and urban wastewaters.

Dupouy V, Doublet B, Arpaillange N, Praud K, Bibbal D, Brugère H, Oswald E, Cloeckaert A, Toutain PL, Bousquet-Mélou A.

Environ Microbiol Rep. 2016 Oct;8(5):789-797. doi: 10.1111/1758-2229.12440. Epub 2016 Aug 25.

PMID:
27402421
27.

The Impact of Competition and Allelopathy on the Trade-Off between Plant Defense and Growth in Two Contrasting Tree Species.

Fernandez C, Monnier Y, Santonja M, Gallet C, Weston LA, Prévosto B, Saunier A, Baldy V, Bousquet-Mélou A.

Front Plant Sci. 2016 May 4;7:594. doi: 10.3389/fpls.2016.00594. eCollection 2016.

28.

Impact of Timing and Dosage of a Fluoroquinolone Treatment on the Microbiological, Pathological, and Clinical Outcomes of Calves Challenged with Mannheimia haemolytica.

Lhermie G, Ferran AA, Assié S, Cassard H, El Garch F, Schneider M, Woerhlé F, Pacalin D, Delverdier M, Bousquet-Mélou A, Meyer G.

Front Microbiol. 2016 Mar 2;7:237. doi: 10.3389/fmicb.2016.00237. eCollection 2016.

29.

Comment on "In Vitro Effects of Bisphenol A β-D-Glucuronide (BPA-G) on Adipogenesis in Human and Murine Preadipocytes".

Gayrard V, Gauderat G, Lacroix MZ, Viguié C, Bousquet-Melou A, Toutain PL, Picard-Hagen N.

Environ Health Perspect. 2015 Dec;123(12):A289. doi: 10.1289/ehp.1510315. No abstract available.

30.

Bisphenol A glucuronide deconjugation is a determining factor of fetal exposure to bisphenol A.

Gauderat G, Picard-Hagen N, Toutain PL, Corbel T, Viguié C, Puel S, Lacroix MZ, Mindeguia P, Bousquet-Melou A, Gayrard V.

Environ Int. 2016 Jan;86:52-9. doi: 10.1016/j.envint.2015.10.006. Epub 2015 Oct 24.

PMID:
26540084
31.

Bacterial Species-Specific Activity of a Fluoroquinolone against Two Closely Related Pasteurellaceae with Similar MICs: Differential In Vitro Inoculum Effects and In Vivo Efficacies.

Lhermie G, El Garch F, Toutain PL, Ferran AA, Bousquet-Mélou A.

PLoS One. 2015 Oct 27;10(10):e0141441. doi: 10.1371/journal.pone.0141441. eCollection 2015.

32.

Allometric scaling for predicting human clearance of bisphenol A.

Collet SH, Picard-Hagen N, Lacroix MZ, Puel S, Viguié C, Bousquet-Melou A, Toutain PL, Gayrard V.

Toxicol Appl Pharmacol. 2015 May 1;284(3):323-9. doi: 10.1016/j.taap.2015.02.024. Epub 2015 Mar 7.

PMID:
25759244
33.

Comparison of the reduction in the antibacterial potency of a fluoroquinolone conferred by a single mutation in the quinolone resistance-determining region or by the inoculum size effect.

Ferran AA, Toutain PL, Bousquet-Melou A.

Int J Antimicrob Agents. 2014 Nov;44(5):472-4. doi: 10.1016/j.ijantimicag.2014.07.007. Epub 2014 Aug 23. No abstract available.

PMID:
25442360
34.
35.

Use of Monte Carlo simulation to determine pharmacodynamic cutoffs of amoxicillin to establish a breakpoint for antimicrobial susceptibility testing in pigs.

Rey JF, Laffont CM, Croubels S, De Backer P, Zemirline C, Bousquet E, Guyonnet J, Ferran AA, Bousquet-Melou A, Toutain PL.

Am J Vet Res. 2014 Feb;75(2):124-31. doi: 10.2460/ajvr.75.2.124.

PMID:
24471748
36.

Low or high doses of cefquinome targeting low or high bacterial inocula cure Klebsiella pneumoniae lung infections but differentially impact the levels of antibiotic resistance in fecal flora.

Vasseur MV, Laurentie M, Rolland JG, Perrin-Guyomard A, Henri J, Ferran AA, Toutain PL, Bousquet-Mélou A.

Antimicrob Agents Chemother. 2014;58(3):1744-8. doi: 10.1128/AAC.02135-13. Epub 2014 Jan 6.

37.

Interpreting bisphenol a absorption in the canine oral cavity: Gayrard et al. Respond.

Gayrard V, Lacroix MZ, Collet SH, Viguié C, Bousquet-Melou A, Toutain PL, Picard-Hagen N.

Environ Health Perspect. 2013 Nov-Dec;121(11-12):A323-4. doi: 10.1289/ehp.1307424R. No abstract available.

38.

Pharmacokinetic/pharmacodynamic assessment of the effects of parenteral administration of a fluoroquinolone on the intestinal microbiota: comparison of bactericidal activity at the gut versus the systemic level in a pig model.

Ferran AA, Bibbal D, Pellet T, Laurentie M, Gicquel-Bruneau M, Sanders P, Schneider M, Toutain PL, Bousquet-Melou A.

Int J Antimicrob Agents. 2013 Nov;42(5):429-35. doi: 10.1016/j.ijantimicag.2013.07.008. Epub 2013 Aug 19.

PMID:
24021905
39.

Persistence and prevalence of pathogenic and extended-spectrum beta-lactamase-producing Escherichia coli in municipal wastewater treatment plant receiving slaughterhouse wastewater.

Diallo AA, Brugère H, Kérourédan M, Dupouy V, Toutain PL, Bousquet-Mélou A, Oswald E, Bibbal D.

Water Res. 2013 Sep 1;47(13):4719-29. doi: 10.1016/j.watres.2013.04.047. Epub 2013 May 3.

PMID:
23774186
40.

High bioavailability of bisphenol A from sublingual exposure.

Gayrard V, Lacroix MZ, Collet SH, Viguié C, Bousquet-Melou A, Toutain PL, Picard-Hagen N.

Environ Health Perspect. 2013 Aug;121(8):951-6. doi: 10.1289/ehp.1206339. Epub 2013 Jun 12.

41.

The consequences of generic marketing on antibiotic consumption and the spread of microbial resistance: the need for new antibiotics.

Toutain PL, Bousquet-Melou A.

J Vet Pharmacol Ther. 2013 Oct;36(5):420-4. doi: 10.1111/jvp.12061. Epub 2013 May 29. Review.

PMID:
23713785
42.

Allelochemicals of Pinus halepensis as drivers of biodiversity in Mediterranean open mosaic habitats during the colonization stage of secondary succession.

Fernandez C, Santonja M, Gros R, Monnier Y, Chomel M, Baldy V, Bousquet-Mélou A.

J Chem Ecol. 2013 Feb;39(2):298-311. doi: 10.1007/s10886-013-0239-6. Epub 2013 Jan 18.

PMID:
23328817
43.

Should licking behavior be considered in the bioavailability evaluation of transdermal products?

Toutain PL, Modric S, Bousquet-Mélou A, Sallovitz JM, Lanusse C.

J Vet Pharmacol Ther. 2012 Apr;35 Suppl 1:39-43. doi: 10.1111/j.1365-2885.2012.01380.x.

PMID:
22413790
44.

Assessment of the genotoxicity of quinolone and fluoroquinolones contaminated soil with the Vicia faba micronucleus test.

Khadra A, Pinelli E, Lacroix MZ, Bousquet-Melou A, Hamdi H, Merlina G, Guiresse M, Hafidi M.

Ecotoxicol Environ Saf. 2012 Feb;76(2):187-92. doi: 10.1016/j.ecoenv.2011.10.012. Epub 2011 Nov 1.

PMID:
22047769
45.

Laparoscopic-assisted colopexy and sterilization in male dogs: short-term results and physiologic consequences.

Mathon DH, Palierne S, Meynaud-Collard P, Layssol-Lamour C, Dulaurent-Ferrieres A, Colson A, Lacroix M, Bousquet-Melou A, Delverdier M, Autefage A.

Vet Surg. 2011 Jun;40(4):500-8. doi: 10.1111/j.1532-950X.2011.00835.x. Epub 2011 Apr 26.

PMID:
21521243
46.

Licking behaviour induces partial anthelmintic efficacy of ivermectin pour-on formulation in untreated cattle.

Bousquet-Mélou A, Jacquiet P, Hoste H, Clément J, Bergeaud JP, Alvinerie M, Toutain PL.

Int J Parasitol. 2011 Apr;41(5):563-9. doi: 10.1016/j.ijpara.2010.12.007. Epub 2011 Jan 11.

47.

Impact of early versus later fluoroquinolone treatment on the clinical; microbiological and resistance outcomes in a mouse-lung model of Pasteurella multocida infection.

Ferran AA, Toutain PL, Bousquet-Mélou A.

Vet Microbiol. 2011 Mar 24;148(2-4):292-7. doi: 10.1016/j.vetmic.2010.09.005. Epub 2010 Sep 15.

48.

Emergence of resistant Klebsiella pneumoniae in the intestinal tract during successful treatment of Klebsiella pneumoniae lung infection in rats.

Kesteman AS, Perrin-Guyomard A, Laurentie M, Sanders P, Toutain PL, Bousquet-Mélou A.

Antimicrob Agents Chemother. 2010 Jul;54(7):2960-4. doi: 10.1128/AAC.01612-09. Epub 2010 May 10.

49.

Species differences in pharmacokinetics and pharmacodynamics.

Toutain PL, Ferran A, Bousquet-Mélou A.

Handb Exp Pharmacol. 2010;(199):19-48. doi: 10.1007/978-3-642-10324-7_2. Review.

PMID:
20204582
50.

Influence of inoculum size and marbofloxacin plasma exposure on the amplification of resistant subpopulations of Klebsiella pneumoniae in a rat lung infection model.

Kesteman AS, Ferran AA, Perrin-Guyomard A, Laurentie M, Sanders P, Toutain PL, Bousquet-Mélou A.

Antimicrob Agents Chemother. 2009 Nov;53(11):4740-8. doi: 10.1128/AAC.00608-09. Epub 2009 Sep 8.

Supplemental Content

Loading ...
Support Center